Comirnaty/Comirnaty pediátrica/Comirnaty bivalente (BNT162b2) |
Pfizer-BioNtech (co-desarrollo) |
Estados Unidos - Alemania |
ARN mensajero |
Polack et al. (2020)POLACK, F. et al. The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against Covid-19≥ 7 days after the 2nd dose. Annals of Internal Medicine, Philadelphia, v. 383, 2020.
|
90 países |
Manufactura en plantas propias, sistema “redundante” para evitar cuellos de botella (Bourla, 2022BOURLA, A. Moonshot: Inside Pfizer’s nine-month race to make the impossible possible. New York: Harper Busness, p.197-214, 2022.) |
SI |
SI |
US$23.15 |
Spikevax/Bivariant Spikevax (mRNA-1273) |
Moderna-Instituto Nacional de Alergias y Enfermedades Infecciosas (co-desarrollo) |
Estados Unidos |
ARN mensajero |
Baden et al. (2021)BADEN, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. The New England Journal of Medicine, Waltham, v. 5, n. 384, p. 403-416, 2021.. |
54 países |
Manufactura en plantas propias + contrato con Lonza para producción en sus plantas de USA y Suiza (Harbert, 2020HARBERT, T. How Moderna is racing to a coronavirus vaccine. Boston: MIT Sloan School of Management. 2020.) |
SI |
SI |
US$25.50 |
ChAdOx1 nCoV- 19 vaccine (AZD1222) |
Oxford-Astrazeneca (acuerdo de licencia público-privado para escalado y manufactura) |
Reino Unido |
Vector viral no replicativo |
Voysey et al. ( 2021)VOYSEY, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, Amsterdam, v. 397, n. 10269, p. 99-111, 2021.
|
154 países |
Licencia exclusiva de tecnología de la Universidad de Oxford a Astrazeneca (empresa doméstica). Manufactura descentralizada en diversos países (Garrison, 2020GARRISON, C. How the ‘Oxford’Covid-19 vaccine became the ’AstraZeneca’ Covid-19 vaccine. Medicines Law & Policy, Israel, 2020. Disponible en: <www.medicineslawandpolicy.org>. Acceso en: 28 dic. 2023. www.medicineslawandpolicy.org...
) |
SI |
SI |
US$2.15 (EU), US$5.25 |
Sputnik V (Gam-COVID-Vac) |
Instituto Gamaleya |
Rusia |
Vector viral no replicativo |
Logunov et al. (2021)LOGUNOV, D. Y. et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet, Amsterdam, v. 397, n. 10275, p. 671-681, 2021.
|
69 países |
Manufactura en empresas rusas inicialmente. Luego, descentralización de la producción. |
NO |
NO |
Inferior than US$10 |
BBIBP-CorV |
Sinopharm + China National Biotec Group Co + Beijing Institute of Biological Products (co-desarrollo) |
China |
Virus Inactivado |
Yao et al. (2022)YAO, T. et al. Immune persistence induced by two-dose BBIBP-CorV vaccine with different intervals, and immunogenicity and safety of a homologous booster dose in high-risk occupational population. Expert Review of Vaccines, London, v. 21, n. 12, p. 1883-1893, 2022.
|
55 países |
Producción doméstica. |
SI |
SI |
US$37.50 |
Ad26.COV2.S |
Janssen Pharmaceutical (Johnson & Johnson) |
Estados Unidos |
Vector viral no replicativo |
Hardt et al. (2022)HARDT, K. et al. Efficacy, safety, and immunogenicity of a booster regimen of Ad26. COV2. S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Infectious Diseases, Amsterdam, v. 22, n. 12, p. 1703-1715, 2022.
|
52 países |
Manufactura descentralizada. |
SI |
SI |
US$10 |
CoronaVac |
Sinovac Research and Development Co., Ltd |
China |
Virus inactivado |
Niyomnaitham et al. (2022) |
33 países |
Producción mayormente doméstica. |
NO |
SI |
US$13.60 |